Ark restructures; Genentech sees promise in preclinical cancer therapy

@FierceBiotech: BMS forges $885M deal to buy ZymoGenetics. Article | Follow @FierceBiotech

 @JohnCFierce: Boston-based Rhythm expands Series A to $40M with Third Rock jumping in. Article | Follow @JohnCFierce 

> London-based Ark Therapeutics has announced a restructuring and a refocus of its R&D program. Andrew Christie has decided to step down from his role as chairman, and Iain Ross, who has been working with the board and Martyn Williams, CEO, to re-structure the business, has agreed to take on the role of executive chairman. Release

> Genentech's GDC-0941 produced promising animal data for ovarian and breast cancer. The drug is a part of a new class of drugs that targets the PI3K protein. Story

> Shares of Santarus spiked this morning on the news that it gained U.S. manufacturing and commercial rights for the diabetes drug Cycloset, which will launch later this year. Report

> GlycoMimetics, a privately held biotechnology company that has raised a total of $63 million in three rounds of venture financing, will move to a larger corporate headquarters in Gaithersburg this November. Item

> Terry Minton, a Louisville resident and former president and CEO of Aptamera Inc., has been named president, CEO and chairman of the board of directors for Naprogenix, a Lexington-based drug discovery and plant biotechnology company. Article

> Researchers at the University of British Columbia have found a link between testosterone and young age with combative, aggressive behavior in CEOs, including hostile takeovers. According to their research, young, male CEOs are four percent more likely to make an offer, and they're also more likely to turn down low-ball offers. Article

And Finally...Chinese officials plan to step up their surveillance efforts designed to spot any appearance of a new NDM-1 superbug. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.